Jaguar Health to Report Phase 3 OnTarget Trial Results for Crofelemer on July 23rd

Jaguar Health, Inc. will hold an investor webcast on July 23, 2024, at 8:30 AM Eastern to reveal results from its phase 3 OnTarget trial of crofelemer for preventing diarrhea in adult cancer patients with solid tumors undergoing targeted therapy. The webcast will also provide updates on Jaguar's cancer supportive care portfolio. Participants will include Jaguar's scientific team, patient advocates, and leading oncology experts discussing cancer therapy-related diarrhea (CTD) and oral mucositis.

Jaguar Health expands its Make Cancer Less Shitty (MCLS) patient advocacy program to include MCLS Ambassadors. These ambassadors, cancer survivors who have faced the side effects of cancer treatments, advocate for better supportive care.

Cancer patients with diarrhea are 40% more likely to discontinue their therapy. Oral mucositis affects up to 40% of chemotherapy patients and 90% of those receiving chemoradiation for head and neck cancers, with many stopping treatment due to the side effects.

On the same day, Jaguar will report the OnTarget trial outcomes in a press release. The company recently acquired a U.S. in-license for Gelclair®, an FDA-approved oral mucositis treatment, and began its promotion at major oncology meetings.